Releases Details

Gaithersburg, Maryland – 12 March 2018: MaxCyte announced today that Debra K. Bowes, Executive Vice President, Business and Strategic Development, will present at two key life sciences conferences this month: the 12^th Annual International Partnering Conference: BIO Europe Spring on March 14 at 9:45 a.m. CET (Amsterdam RAI Convention Center, Amsterdam) and the 2018 Sachs BioCapital USA Forum  on March 21 at 2:40 p.m. EST (New York Academy of Sciences, New York, NY).

Ms. Bowes will present and discuss MaxCyte’s next-generation autologous CAR (chimeric antigen receptor) therapies. In her presentation, Ms. Bowes will focus on how MaxCyte’s breakthrough CARMA platform in immuno-oncology has the ability to engineer transient persistence to mitigate off-tumor toxicity and significantly reduce the turnaround time of autologous cell therapy to patients.

“We’re excited to share the progress we’ve made in advancing our novel and proprietary CARMA platform and CAR therapy drug candidates with scientific and industry audiences at these two important life sciences meetings,” said Ms. Bowes. “Our goal is to advance our first CAR therapy into the clinic this year, and we are excited to have a forum to share the potential for our CARMA platform’s approach in a broad range of targets and cancers, including solid tumors, while reducing potential adverse events that have been evident with previous CAR technologies.

More information on the conferences can be found at //ebdgroup.knect365.com/bioeurope-spring/ for Bio Europe Spring and at //www.sachsforum.com/bcusa-about.html for Sachs BioCapital USA.

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 50 partnered programme licenses in cell therapy including more than 20 licensed for clinical use in cell therapy. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.

For more information, visit www.maxcyte.com

###